Gilead Sciences Announces Positive Phase 2 Studies Data and AutoNavi Holdings to be acquired by Alibaba Group Holding Limited for $1.5B

Gilead Sciences Inc. (NASDAQ: GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi® (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. “The patients included in these analyses are historically among the most difficult to cure, and many have had no appropriate treatment options until now,” said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer, Gilead Sciences. “These